http://jpadr.com/index.php/jpadr <p>The Journal of Pharmacovigilance and Drug Research (JPADR) is the official publication of the Global Pharmacovigilance Society. This is an international, open access, and peer-reviewed scientific journal. It focuses on pharmacovigilance studies and their associated topics such as adverse drug reaction, drug clinical trials, drug effectiveness and efficacy, drugs risk management, as well as all aspects related to the safe use of drugs.</p> <p>The JPADR is oriented to researchers, professors, students, and practitioners from both the pharmaceutical industry sector, as well as the wide range of health and medicine arenas. The journal’s objective is to establish a formal platform for communicating the research results on pharmacovigilance.</p> <p><strong>Aims and Scope</strong></p> <p>The Journal of Pharmacovigilance and Drug Research (JPADR) is the official publication of the Global Pharmacovigilance Society. This is an international, open access, and peer-reviewed scientific journal. It focuses on pharmacovigilance studies and their associated topics such as adverse drug reaction, drug clinical trials, drug effectiveness and efficacy, drugs risk management, as well as all aspects related to the safe use of drugs.</p> <p>Authors can submit manuscripts related to&nbsp;</p> <p>1. Pharmacovigilance</p> <p>2. Materiovigilance/Technovigilance</p> <p>3. Ecopharmacovigilance</p> <p>4. Ayurvedic drugs safety</p> <p>5. Pharmacology</p> <p>6. Computer-aided drug design</p> <p>7. Formulation of pharmaceutical research and development</p> <p>8. Animal Study</p> <p>9. Preclinical trials</p> <p>10. Clinical trials</p> <p>11. Biotechnology</p> <p>12. Pharmacoepidemiology</p> <p>13. Ergonomics</p> <p>14. Newly identified drug</p> <p>15. Haemovigilance</p> <p>16. Artificial Intelligence and Machine Learning in Pharmaceutical Drug Development</p> <p>The JPADR is oriented to researchers, professors, students, and practitioners from both the pharmaceutical industry sector, as well as the wide range of health and medicine arenas. The journal’s objective is to establish a formal platform for communicating the research results on pharmacovigilance.</p> <p><strong>Ethical code</strong></p> <p>Before submitting an article for possible publication in the journal, we recommend that you read our <a href="https://jpadr.com/index.php/jpadr/Publication-Ethics" target="_blank" rel="noopener">code of ethics for authors</a><strong>.</strong></p> <p><strong>Article Processing Charge (APC)</strong></p> <p>Publication in the JPADR is subject to APC, more information can be found <a href="https://jpadr.com/index.php/jpadr/APC-and-Waiver-Policy" target="_blank" rel="noopener">here</a><strong>.</strong></p> <p><strong>Publication frequency</strong></p> <p>The journal has a quarterly frequency. Four issues are published a year that cover the periods January-March, April-June, July-September, and October-December.</p> <p><strong>Open access statement</strong></p> <p>The JPADR is loyal to open access, allowing any users to read, download, copy, distribute, print, search, or link to the full texts of its articles and to use them for any other lawful purpose. All the articles published in the journal have immediate free access from their publication date. We do not charge any fees for reading or downloading articles.</p> <p><strong>Archiving</strong></p> <p>The published contents in the journal are archived in the <a href="https://jpadr.com/index.php/jpadr/gateway/clockss" target="_blank" rel="noopener">CLOCKSS</a> and <a href="https://jpadr.com/index.php/jpadr/gateway/lockss" target="_blank" rel="noopener">LOCKSS</a> systems.</p> <p><strong>License and copyright </strong></p> <p>Articles in the JPADR are published under the <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" target="_blank" rel="noopener">CC BY-NC-ND 4.0</a> License. This allows authors the reproduction of articles, free of charge, for non-commercial use only, and with the appropriate citation information. All authors publishing in the JPADR retain copyright over their work.</p> <p><strong>Society information</strong></p> <p>The <a href="https://globalpvs.com/" target="_blank" rel="noopener">Global Pharmacovigilance Society</a> is composed of a team of pharmacovigilance professionals and leaders across the world aimed to protect patients from any serious adverse event following the administration of any drug. The objective of this society is to improve patient and drug safety. We discuss the strategies to strengthen the pharmacovigilance system. We tend to organize webinars, conferences, and camps to create awareness among the public for adverse drug reactions (ADR) reporting.</p> <p>&nbsp;</p> <p>&nbsp;</p> Global Pharmacovigilance Society en-US Journal of Pharmacovigilance and Drug Research 2582-7235 http://jpadr.com/index.php/jpadr/article/view/226 <p style="font-weight: 400;">Background:&nbsp;Decitabine in combination with Venetoclax is widely used in elderly patients with Acute Myeloid Leukemia. Profound myelosuppression is expected; however, unusual mucocutaneous manifestations such as black discoloration of the tongue are rarely documented.&nbsp;It has been established that patients can develop significant side effects, including serious myelosuppression, from treatment with decitabine and venetoclax.</p> <p style="font-weight: 400;">Case Presentation: This clinical report describes the development of a blackish discoloration of the dorsal surface of the tongue (black hairy tongue) in a 66-year-old male AML patient who experienced pancytopenia (a decrease in all types of blood cells) while undergoing decitabine-based chemotherapy with venetoclax. The patient developed black hairy tongue due to profound immunosuppression and experienced the following adverse events during his hospital stay: bacteremia, septic shock, maximum grade of all types of blood dyscrasia, itching, thrush, fecal and urine incontinence, worsening/coughing, fever, and poor mitochondrial activity.</p> <p style="font-weight: 400;">Conclusion: This case study illustrates rare oral complications associated with hypomethylating agents in AML patients with significant dyscrasia and emphasizes the need for close monitoring of all oral healthcare needs for patients who are significantly cytopenic.</p> Satish Kumar Basattikoppalu Puttegowda Ajish Muthangayil Mohith Shivaramu Pooja Anjanappa Copyright (c) 2026 Satish Kumar Basattikoppalu Puttegowda, Ajish Muthangayil, Mohith Shivaramu, Pooja Anjanappa https://creativecommons.org/licenses/by/4.0/ 2026-03-01 2026-03-01 7 1 1 3